Cell Therapy · global
CAR-T Moves into Autoimmune Diseases: Safety Risks Emerge Behind Hopes of Stopping Medication
Cell therapy continues to attract funding, but a fatal infection in BMS’s multiple sclerosis trial highlights a reminder for developers: the promise of long-term remission from a single treatment must be weighed alongside comprehensive evidence of risk.
For patients with autoimmune diseases who require long-term medication, a single cell therapy that could deliver lasting remission would mark a major turning point in their lives. Yet as CAR-T moves from cancer treatment into chronic diseases, the toll of treatment has become a central question alongside efficacy. On November 2, BioSpace highlighted the tension between rising cell therapy investment and safety events; multiple sclerosis data recently released by Bristol Myers Squibb (BMS) gave those risks a more concrete outline.
On October 23, BMS announced that the multiple sclerosis cohort in its Phase 1 Breakfree-2 trial included 66 participants with highly active relapsing and progressive disease. The trial uses a single-arm, dose-escalation design, primarily to assess safety. The investigational treatment, zola-cel, is an autologous CD19 CAR-T therapy that modifies patients’ T cells and infuses them back into the body to eliminate B cells, exploring the possibility of resetting the immune system.
The most serious event occurred after the data cutoff. According to the company, one patient developed delayed-onset motor symptoms after infusion that were not classified as immune effector cell-associated neurotoxicity syndrome (ICANS). The symptoms persisted despite intermittent treatment with steroids and intravenous immunoglobulin. The patient subsequently received high-dose cyclophosphamide, then developed fatal septic pneumonia and died on day 44 after infusion. This sequence involved multiple treatments and clinical changes, and publicly available information is not yet sufficient to clarify each factor’s contribution to the death.
Other safety data also showed that immune responses require close management: 28 of the 66 participants developed cytokine release syndrome, all Grade 1 or 2; another 5 experienced ICANS, including one Grade 4 event that resolved within four days following treatment. The fact that most events were transient and reversible must be considered alongside the risks revealed by the severe cases as part of the same overall safety picture.
Efficacy signals provide a reason to continue research. All 60 participants treated at the second dose level were off disease-modifying therapy at their last follow-up, including 9 who had been followed for more than 12 months. However, remaining off medication does not establish lasting remission. This is an early trial without a control group, and follow-up duration varies, so the findings cannot yet establish that the therapy is superior to existing treatments or can prevent disability progression over the long term.
### Background Context
The same wave of autoimmune cell therapy development also includes Nkarta’s efforts to bring its off-the-shelf CAR-NK candidate NKX019 into community trial sites and explore outpatient administration. This approach aims to lower barriers to care, but CAR-NK and CAR-T use different cells, so safety conclusions cannot be directly transferred between them. Whether treatment can move beyond highly specialized centers still depends on the evidence for each product and the ability of staff on site to recognize and manage complications.
Investment can support more trials, but it cannot replace long-term follow-up. For these therapies, the next question is which patients can achieve improvements lasting long enough to justify the risks of cell therapy and related interventions. BMS’s data leave both hope for stopping medication and a safety warning, underscoring that both must be examined together in more comprehensive research.